Skip to content

Advertisement

  • Case report
  • Open Access
  • Open Peer Review

A novel homozygous mutation in the glycerol-3-phosphate dehydrogenase 1 gene in a Chinese patient with transient infantile hypertriglyceridemia: a case report

BMC Gastroenterology201818:96

https://doi.org/10.1186/s12876-018-0827-6

  • Received: 10 February 2018
  • Accepted: 19 June 2018
  • Published:
Open Peer Review reports

Abstract

Background

Transient infantile hypertriglyceridemia (HTGTI) is an autosomal recessive disorder caused by mutations in the glycerol-3-phosphate dehydrogenase 1 (GPD1) gene.

Case presentation

We report a case of HTGTI in a Chinese female infant. She presented with hepatomegaly, hypertriglyceridemia, moderately elevated transaminases, and hepatic steatosis at 3.5 months of age. A novel mutation c.523C>T, p. (Q175*) was identified in GPD1. The patient was a homozygote and her parents were heterozygous for the mutation. Ultrastructural study showed intrahepatocytic lipid droplets.

Conclusions

This is the first reported case of HTGTI in Chinese, expanding the worldwide distribution of HTGTI and the mutation spectrum of GPD1.

Keywords

  • Hypertriglyceridemia
  • GPD1
  • hepatomegaly
  • hepatic steatosis
  • HTGTI

Background

The glycerol-3-phosphate dehydrogenase 1 (GPD1; MIM 138420) gene, which is mapped to chromosome 12q12-q13, encodes cytoplasmic NAD-dependent GPD1 that is crucial in both carbohydrate and lipid metabolism by catalyzing the reversible redox reaction of dihydroxyacetone phosphate (DHAP) and reduced nicotine adenine dinucleotide (NADH) to glycerol-3-phosphate (G3P) and NAD+ [1, 2]. Under physiological conditions, the reaction strongly favors the formation of G3P [2]. Glycerol-3-phosphate dehydrogenase 2 (GPD2; MIM 138430) is located on the outer surface of the inner mitochondrial membrane and catalyzes the unidirectional reaction of G3P and flavin adenine dinucleotide (FAD) to DHAP and FADH2 [2]. Together with a mitochondrial GPD2, GPD1 forms the G3P shuttle mainly in the brain and skeletal muscle of mammals, which transfers reducing equivalents from the cytosol to the mitochondria [3]. The human GPD1 is organized into two distinct domains, the N-terminal eight-stranded β-sheet sandwich domain (from residues 3–190) and the C-terminal helical substrate-binding (from residues 193–349) domain [2]. NAD+ binds to GPD1 at the periphery of its β-sheet core (10-GSGNWG-15) [2].

GPD1 mutations were first identified by Basel-Vanagaite et al. as the cause of transient infantile hypertriglyceridemia (HTGTI; OMIM 614480) in 10 individuals from four consanguineous Israeli Arab families carrying a homozygous founder mutation c.361-1G>C [3]. HTGTI manifests as early onset hepatomegaly, hypertriglyceridemia, moderately elevated transaminases, hepatic steatosis, and hepatic fibrosis [3]. Recently, Li et al. reported biallelic mutations in GPD1 gene of a Chinese boy who presented with a different phenotype comprising obesity, insulin resistance, fatty liver, and short stature [4]. To date, only four reports have described 16 patients harboring homozygous or compound heterozygous mutations in the GPD1 gene [36]. Here, we describe a Han Chinese patient with a novel GPD1 homozygous mutation who presented with hepatomegaly, elevated transaminases, hypertriglyceridemia, and fatty liver in infancy.

Case presentation

This study was approved by the Research Ethics Committee of Children’s Hospital of Fudan University and was conducted under the Declaration of Helsinki ethical principles for medical research involving human subjects. Informed consent was obtained from the child’s parents.

Patient

The female patient was the second child of a non-consanguineous Han Chinese couple. The mother previously had four episodes of spontaneous abortion during the first trimester due to lack of mixed lymphocyte reaction blocking antibodies. Through paternal lymphocyte immunotherapy, the mother successfully gave birth to the proband and her older brother. Fetal ultrasound scans of the proband showed fetal liver was normal. She was born at the gestational age of 39 weeks by cesarean section, with a birth weight of 3.15 kg. She presented at the age of 3 months and 14 days with bronchopneumonia, during the course of which elevated alanine aminotransferase (101 U/L, normal: 0-40 U/L) and aspartate aminotransferase (135 U/L, normal: 0-40 U/L) were noted. Initial abdominal ultrasound revealed hepatomegaly (the liver enlarged 2 cm below the costal margin). As the elevated liver enzymes and hepatomegaly persisted after recovery of bronchopneumonia, the child was transferred to another hospital for further treatment. Fasting hypertriglyceridemia was noted at presentation and throughout the follow-up period (range 4.39-10.94 mmol/L, normal: 0.56-1.7 mmol/L). Gamma-glutamyltranspeptidase and total bile acids were 265 IU/L (normal: 7-50 IU/L) and 18.2 μmol/L (normal: 0-10 μmol/L), respectively. However, total cholesterol, lipoprotein, bilirubin, alpha-fetoprotein and synthetic liver function (coagulation studies and albumin) were within normal limits. Abdominal CT scan showed a severely enlarged liver accompanied with fatty change, which had diffusely decreased density. Viral serological markers (hepatotrophic viruses, Epstein-Barr virus, cytomegalovirus, and HIV), toxoplasma, thyroid function tests, creatine phosphokinase, glucose, ceruloplasmin, blood routine tests, urine routine tests, blood lactate, blood ammonia, carbonyldiamide, creatinine, uric acid, urine organic acids, autoimmune serology, immunoglobulin levels, and echocardiogram were unremarkable. At this point, due to the combination of hypertriglyceridemia, hepatomegaly, and elevated liver transaminases, the working diagnosis was inclined to inherited metabolic liver disease. Thus, the whole blood samples from the family were sent to Precision MD (Beijing, China) for panel sequencing to screen 4503 genes using the customized xGen Inherited Diseases Panel. She took “Compound Glycyrrhizin” during this hospitalization. However, the levels of triglyceride and liver enzymes were not decreased. She was referred to the center for pediatric liver diseases in our hospital at 6.5 months of age for percutaneous liver biopsy. Since then, she did not receive any treatment. At the last evaluation at the age of 1 year and 3 months, the child still presented with hepatomegaly, hypertriglyceridemia, and moderately elevated transaminases, while maintaining a normal growth and psychomotor development. The detailed clinical characteristics of the proband are shown in Table 1. The patient’s parents and older brother were asymptomatic. The liver functions of the mother and older brother were normal. However, alanine aminotransferase (59 IU/L, normal: 0-40 IU/L), gamma-glutamyl transpeptidase (62 IU/L, normal: 7-50 IU/L), total cholesterol (5.87 mmol/L, normal: 3.1-5.2 mmol/L) and triglyceride (3.5 mmol/L, normal: 0.56-1.7 mmol/L) were mildly elevated in the father. In addition, the father was morbidly obese (body mass index 31.3 kg/m2, normal: 18.5-23.9 kg/m2).
Table 1

Clinical and laboratory findings of the patient

Personal history

 Presenting age (months)

3.5

 Age at last following up (months)

15

 Gravidity (G) and Parity (P)

G6P2

 Gestation (weeks)

39

 Birth weight (g)

3150

 Birth history

cesarean section

Physical examination at 6.5 months old

 Head circumference (cm)

42.0

 Chest circumference (cm)

43.0

 Height (cm)

63.0

 Weight (kg)

6.8

 Temperature (°C)

37.0

 Heart rate (beats per minute)

126

 Respiration rate (times per minute)

28

 Hepatomegaly

Yes

 Splenomegaly

No

Biochemical examination

 Albumin (g/L)

45.1-50.8

 Alanine aminotransferase (IU/L)

68-110

 Aspartate aminotransferase (IU/L)

108-186

 Gammaglutamyl-transpeptidase (IU/L)

233-482

 Direct bilirubin (umol/L)

1.0-2.3

 Total bilirubin (umol/L)

2.4-9.4

 Total bile acid (umol/L)

9.0-19.8

 Alpha fetal protein (ng/mL)

53

 Triglyceride (mmol/L)

4.18-10.94

 Total cholesterol (mmol/L)

2.36-4.35

 Glucose (mmol/L)

4.2-5.7

Coagulation test

 D-dimer (mg/L)

0.27-1.18

 Activated partial thromboplastin time (s)

25.0-33.3

 Thrombin time (s)

19.4-19.9

 Prothrombin time (s)

11.0-13.3

 Fibrinogen (g/L)

1.84-1.93

Blood routine examination

 Hemoglobin (g/L)

95.0-101.0

 Red blood cell count (per liter)

4.91-5.24 × 1012

 White blood cell count (per liter)

7.7-11 × 109

 Lymphocytes (%)

65.0-75.0

 Neutrophils (%)

16.8-22.0

 Platelets count (per liter)

568-782 × 109

Genetic analysis

Written informed consent was obtained prior to the collection of peripheral blood from the proband and her family members. All the blood samples were sent to Precision MD (Beijing, China) for sequencing. Genomic DNA of all the family members was extracted from their peripheral blood leukocytes according to the manufacturer's standard procedure using the QIAamp DNA Blood Midi Kit (Qiagen, Hilden, Germany). Genomic DNA of the proband underwent panel sequencing to screen 4503 genes using the customized xGen Inherited Diseases Panel. DNA was fragmented by Covaris LE220 (Massachusetts, USA) to generate paired-end library (200–250 bp). Targets were captured using xGen Lockdown Probes (Precision MD, Beijing, China). The captured libraries were sequenced using the Illumina hiseq2500 Analyzers following the manufacturer’s instructions (Illumina, San Diego, USA). The reads were mapped to human genome reference (hg19) using Burrows-Wheeler Aligner (http://bio-bwa.sourceforge.net/). Single-nucleotide variants and indels were called with SOAPsnp (The Beijing Genomics Institute in-house software) and Samtools (http://samtools.sourceforge.net/). All single-nucleotide variants and indels were filtered via multiple databases. Pathogenic variants were assessed under the protocol issued by the American College of Medical Genetics and Genomics [7]. Mutations were verified in the proband and her family members by Sanger sequencing.

Molecular findings

A homozygous nonsense mutation c.523C>T, p. (Q175*) in GPD1 (NM_005276.3) was identified in the proband. Her parents and older brother were heterozygous for the mutation, consistent with a recessive inheritance (Additional file 1). This variant introduces a stop codon at codon 175, which is predicted to result in nonsense mediated mRNA decay by MutationTaster (http://www.mutationtaster.org/) [8]. The variant was novel and not recorded in Exome Aggregation Consortium Server (http://exac.broadinstitute.org/), NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/) and Thousand Genomes Project (http://www.1000genomes.org/home).

Pathological findings

Liver biopsy was performed at 6.5 months of age. Light microscopy revealed marked micro- and macro- vacuoles in hepatocytes on hematoxylin and eosin stained sections, indicating severe hepatic steatosis (Fig. 1a). Mild lymphocytic inflammatory infiltrates in the portal tracts were also present. Periodic acid Schiff staining showed macro- and micro- vacuoles in hepatocytes (Fig. 1b). Masson staining revealed mild portal fibrosis (Fig. 1c). Immunostaining for cytokeratin 7 and 19 demonstrated slight proliferation of the bile ducts along the ductal plate. Iron, HBsAg, HBcAg and Epstein-Barr virus were negative. Electron microscopy revealed macro- and micro fat and glycogen in the cytoplasm of hepatocytes, indicating severe liver steatosis (Fig. 1d). Increased myeloid body, abundant collagen fibers and mild dilation of bile canaliculi were also observed.
Fig. 1
Fig. 1

The pathological results of the proband. a Marked macro- and microvacuoles were observed (Hematoxylin and Eosin staining; original magnification, ×100). b Periodic acid Schiff staining also showed macro- and microvacuoles in hepatocytes (×200). c Mild fibrosis was presented in portal tracts (Masson staining, ×200). d The arrow showed fats were in the hepatocytes

Discussion and conclusions

HTGTI is a rare autosomal recessive disorder that has been described in a total of 15 affected individuals in three studies [3, 5, 6]. The shared features of these patients include infantile hypertriglyceridemia, elevated liver enzymes, hepatomegaly, liver steatosis and fibrosis. Additional uncommon phenotypes include fasting hypoglycemia and kidney disease. We report the first Han Chinese patient with HTGTI, and the patient carried a novel homozygous nonsense mutation in the GPD1 gene, which is the causative variation. Our patient clinically resembled other reported children with HTGTI: She presented with elevated liver transaminases, hypertriglyceridemia, marked hepatomegaly, and hepatic steatosis since early infancy. Electron microscopy was only undertaken in one of 15 previous affected patients, revealing interhepatocytic, not intrahepatocytic, vesicles (most likely fat) [6]. By contrast, electron microscopy showed intrahepatocytic, not interhepatocytic, lipid droplets in our patient; however, the significance of this difference is unclear. Although our patient was not given treatment since 6.5 months old, the levels of triglyceride and liver enzymes decreased at the last evaluation at the age of 1 year and 3 months. The heterozygote (carrier) parents and older brother of our reported patient were asymptomatic. The mildly elevated liver functions of the father may be due to his high body mass index.

Recently, Li et al. reported biallelic mutations (c.220-2A>G and c.820G>A) in GPD1 gene of a 13-year, 8-month-old Chinese boy who presented with obesity, insulin resistance, fatty liver, dermal abnormalities (facial acne, acanthosis nigricans, and hirsutism), short stature, elevated dehydroepiandrosterone sulfate and lipoprotein-α levels, which were different from HTGTI phenotype [4]. Clinical features and molecular genetics of individuals with biallelic mutations in GPD1 gene were shown in Table 2. Li et al. also suggested that the GPD1 gene should be considered as the short stature causing gene [4]. However, it is uncertain that the different phenotype of the adolescent patient was due to phenotypic heterogeneity or having an unrecognized second disorder.
Table 2

Clinical features and molecular genetics of individuals with biallelic mutations in GPD1 gene

Patient

F1-IV1

F1-IV2

F1-IV4

F2-II6

F2-III1

F3-V1

F3-V2

F3-V3

F4-II4

F4-III3

11

A

B

C

D

16

17

Gender

M

M

M

M

F

F

F

F

M

M

F

M

F

M

M

M

F

Descent

Israeli Arab

Caucasian

Arab-Muslim

NA

Italian

Italian

Chinese

Chinese

Consanguinity

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

NA

Yes

No

Yes

NA

No

No

Term birth

NA

NA

No

NA

Yes

Yes

Yes

Yes

No

No

Yes

NA

Yes

Yes

NA

Yes

Yes

Birth weight (g)

3,000

NA

2,180

3,395

2,570

3,000

2,430

2,190

1,950

2,160

NA

NA

3,500

3,640

NA

2900

3,150

Presenting age (m)

1

1

4–6

Birth

6

2.5

7

7

9

3.5

Birth

10

12

5

24

84

3.5

Age at last test (y)

13.7

9.9

11.9

23

2.9

4.3

1.3

1.3

12.5

12.5

1.5

4.5

4

7

31

NA

1.2

Initial TG (mg/dl)

6244

250

990

520

1208

349

258

330

225

566

839

170

1180

466

213

N

388

Last TG (mg/dl)

250

247

289

170

202

135

185

202

301

434

536

N

N

271

NA

NA

370

TGa(mg/dl)

10–150

50-130

40-150

NA

50-150

Initial CH (mg/dl)

420

109

164

101

109

66

95

99

106

149

197

155

260

N

NA

N

95

Last CH (mg/dl)

73

207

172

114

184

202

118

141

188

256

NA

NA

NA

NN

204

NA

168

CHa (mg/dl)

<170

<170

120-200

NA

120-201

Elevated transaminases

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

Yes

Hepatomegaly

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

Yes

Splenomegaly

NA

NA

No

Yes

NA

No

Yes

Yes

No

No

NA

No

No

Yes

NA

No

No

Hepatic steatosis

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Short stature

No

No

Yes

Yes

No

No

No

No

Yes

Yes

No

NA

NA

No

NA

Yes

No

Other findings

No

No

No

No

No

No

No

No

Horseshoe kidney; Transient hypotonia

Craniocerebral involvement

No

Fasting hypoglycemia

No

Kidney involvement

No

Obesity; Insulin resistance; Dermal abnormalities; EDL

No

Age of liver biopsy

NA

2.5y

4.5y

NA

NA

NA

NA

NA

NA

NA

5m

NA

1y

5m<Age<1y

NA

NA

6.5m

Light microscopy of liver

NA

S; FI; MI

S; FI; MI

NA

NA

NA

NA

NA

NA

NA

S

NA

S; FI

S; C; I

S; FI

NA

S; FI; MI

Electron microscopy of liver

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

Vesicles between the hepatocytes

NA

NA

NA

Lipid droplets in hepatocytes

Mutations (NM_005276)

c.361-1G>C; Homo

R229Q+ a long deletion

Arg269Gln; Homo

c.361- 1G > C; Homo

Cys214Arg; Homo

Cys214Arg; Homo

c.220-2A>G + Ala274Thr

Q175a; Homo

Reference

Basel-Vanagaite et al., 2012

Joshi et al., 2014

Dionisi-Vici et al., 2016

Li et al., 2017

This study

TG triglyceride, CH cholesterol, S steatosis, FI fibrosis, MI mild inflammation, C cirrhosis, I inflammation, EDL elevated dehydroepiandrosterone sulfate and lipoprotein-α levels, NA no available, NN near normal values, N normal, Homo homozygote, F femal, M male, g grams, m months, y years

areference range

Hypertriglyceridemia is a hallmark of many disorders, including metabolic syndrome, diabetes, atherosclerosis, and obesity. Several genetic defects for hypertriglyceridemia have been identified, including mutations in APOA5 (MIM 606368) [9], LIPI (MIM 609252) [10], LPL (MIM 609708) [11], APOC2 (MIM 608083) [12], LIPC (MIM 151670) [13], USF1 (MIM 191523) [14], GPIHBP1 (MIM 612757) [15], and LMF1 (MIM 611761) [16]. GPD1 disease is one of the important molecular etiologies of primary hypertriglyceridemia with onset in infancy [3]. Basel-Vanagaite et al. confirmed that mutation of GPD1 in HepG2 cells causes increased triglyceride synthesis and secretion [3]. However, the exact mechanism of hypertriglyceridemia in GPD1 deficiency is unclear and remains to be further clarified. Notably, high triglyceride level is an independent risk factor for coronary artery disease and also associated with an increased risk of acute pancreatitis [1719]. The long term effects of hypertriglyceridemia on patients with HTGTI is unknown, and it is necessary to pay attention to these patients in their long-term follow up.

All the GPD1 deficiency patients had fatty liver on ultrasound or other imaging examinations. Light microscopy undertaken in 6 of sixteen previous affected patients showed steatosis with varying degree of fibrosis. Joshi M et al. proposed that fatty liver in GPD1 disease may be due to acylation of excess DHAP [5]. The detailed mechanisms are not clear and further research is needed to shed light on them. Fatty liver with hepatomegaly can be caused by a spectrum of inherited metabolic liver diseases, such as glycogen storage disease, lipidosis, lysosomal diseases, and citrin deficiency. Liver biopsy and genetic analysis are both useful for differential diagnosis of HTGTI and those diseases. However, the definite diagnosis of HTGTI depends on genetic testing.

The natural history of HTGTI is not clear yet. Although most patients presented with liver fibrosis in early infancy, all affected individuals had a good prognosis. At the time of their last evaluation, the levels of triglyceride and liver enzymes were improved in most patients. In addition, the oldest patient (aged 31 years) was doing well [6]. Thus, liver transplantation is not recommended for HTGTI patients. Since triglyceride levels could be improved without specific therapy, we don’t recommend lipoprotein apheresis as routine therapy for these patients. But it could be an option for patients with severe hyperlipemia. We recommend to evaluate the growth and development and test liver function, total cholesterol, triglycerides, abdominal ultrasound, FibroScan and other abnormal index in the follow-up visit. In addition, it is necessary to pay attention to coronary artery disease and pancreatitis in their long-term follow up, which is associated with hypertriglyceridemia.

Previously, a total of 5 mutations in the GPD1 gene have been identified in 15 patients with HTGTI. In this study, we reported a novel disease-causing mutation c.523C>T, which is predicted to result in nonsense mediated mRNA decay. Among the 16 patients carrying biallelic mutations in GPD1, 15 patients showed a homozygous mutation, while only 1 patient was compound heterozygotes. The identified variants comprised 1 nonsense (c.523C>T), 3 missense (c.686G>A, c.806G>A, and c.640T>C), 1 splice site variant (c.361-1G>C), and 1 deletion mutation (28.7 kb > the deletion size > 1.85 kb).

In conclusion, we reported a Han Chinese HTGTI patient with mutation of GPD1, having hypertriglyceridemia, hepatomegaly, mildly elevated transaminases, and hepatic steatosis. GPD1 deficiency should also be considered in children and adolescents with hypertriglyceridemia and hepatic steatosis of unknown causes, and that the natural history of the condition is still unknown.

Abbreviations

DHAP: 

Dihydroxyacetone phosphate

FAD: 

Flavin adenine dinucleotide

G3P: 

Glycerol-3-phosphate

GPD1: 

Glycerol-3-phosphate dehydrogenase 1

GPD2: 

Glycerol-3-phosphate dehydrogenase 2

HTGTI: 

Transient infantile hypertriglyceridemia

NADH: 

Reduced nicotine adenine dinucleotide

Declarations

Acknowledgments

The authors are grateful for the support of the family of the patient whom we have studied, and thank referring physicians, nurses, and technical staff.

Funding

This research was supported by the National Natural Science Foundation of China, Grant Numbers 81570468; Shanghai Medical Key Specialty Construction Project Number ZK2015A04.

Availability of data and materials

All data generated or analysed during this study are included in this published article (and its Additional files).

Authors’ contributions

JSW, XBX and JQL drafted the manuscript; JSW, XBX, JQL, KA were involved in the acquisition, analysis and interpretation of clinical and genetic data; YL and YCL were involved in the acquisition, analysis and interpretation of clinical data; JYF and LC performed analysis and interpretation of pathologic data; All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Research Ethics Committee of Children’s Hospital of Fudan University and was conducted under the Declaration of Helsinki ethical principles for medical research involving human subjects. Informed consent was obtained from the child’s parents.

Consent for publication

Written informed consent for publication of clinical details was obtained from the guardians of the patient.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Pediatrics, Jinshan Hospital of Fudan University, 1508 Longhang Road, Jinshan District, Shanghai, 201508, China
(2)
The Center for Pediatric Liver Disease, Children’s Hospital of Fudan University, 399 Wanyuan Road, Minhang District, Shanghai, 201102, China
(3)
Department of Pathology, Children’s Hospital of Fudan University, 399 Wanyuan Road, Minhang District, Shanghai, 201102, China

References

  1. Menaya J, Gonzalez-Manchon C, Parrilla R, Ayuso MS. Molecular cloning, sequencing and expression of a cDNA encoding a human liver NAD-dependent alpha-glycerol-3-phosphate dehydrogenase. Biochim Biophys Acta. 1995;1262:91–4.View ArticlePubMedGoogle Scholar
  2. Ou X, Ji C, Han X, Zhao X, Li X, Mao Y, et al. Crystal structures of human glycerol 3-phosphate dehydrogenase 1 (GPD1). J Mol Biol. 2006;357:858–69.View ArticlePubMedGoogle Scholar
  3. Basel-Vanagaite L, Zevit N, Zahav AH, Guo L, Parathath S, Pasmanik-Chor M, et al. Transient infantile hypertriglyceridemia, fatty Liver, and hepatic fibrosis caused by mutated GPD1, encoding glycerol-3-phosphate dehydrogenase 1. Am J Hum Genet. 2012;90:49–60.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Li N, Chang G, Xu Y, Ding Y, Li G, Yu T, et al. Biallelic mutations in GPD1 gene in a Chinese boy mainly presented with obesity, insulin resistance, fatty liver, and short stature. Am J Med Genet A. 2017;173:3189–94.View ArticlePubMedGoogle Scholar
  5. Joshi M, Eagan J, Desai NK, Newton SA, Towne MC, Marinakis NS, et al. A compound heterozygous mutation in GPD1 causes hepatomegaly, steatohepatitis, and hypertriglyceridemia. Eur J Hum Genet. 2014;22:1229–32.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Dionisi-Vici C, Shteyer E, Niceta M, Rizzo C, Pode-Shakked B, Chillemi G, et al. Expanding the molecular diversity and phenotypic spectrum of glycerol 3-phosphate dehydrogenase 1 deficiency. J Inherit Metab Dis. 2016;39:689–95.View ArticlePubMedGoogle Scholar
  7. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11:361–2.View ArticlePubMedGoogle Scholar
  9. Kao JT, Wen HC, Chien KL, Hsu HC, Lin SW. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet. 2003;12:2533–9.View ArticlePubMedGoogle Scholar
  10. Wen XY, Hegele RA, Wang J, Wang DY, Cheung J, Wilson M, et al. Identification of a novel lipase gene mutated in lpd mice with hypertriglyceridemia and associated with dyslipidemia in humans. Hum Mol Genet. 2003;12:1131–43.View ArticlePubMedGoogle Scholar
  11. Henderson HE, Ma Y, Hassan MF, Monsalve MV, Marais AD, Winkler F, et al. Amino acid substitution (Ile194----Thr) in exon 5 of the lipoprotein lipase gene causes lipoprotein lipase deficiency in three unrelated probands. Support for a multicentric origin. J Clin Invest. 1991;87:2005–11.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Baggio G, Manzato E, Gabelli C, Fellin R, Martini S, Enzi GB, et al. Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients. J Clin Invest. 1986;77:520–7.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Hegele RA, Vezina C, Moorjani S, Lupien PJ, Gagne C, Brun LD, et al. A hepatic lipase gene mutation associated with heritable lipolytic deficiency. J Clin Endocrinol Metab. 1991;72:730–2.View ArticlePubMedGoogle Scholar
  14. Pajukanta P, Lilja HE, Sinsheimer JS, Cantor RM, Lusis AJ, Gentile M, et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet. 2004;36:371–6.View ArticlePubMedGoogle Scholar
  15. Wang J, Hegele RA. Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650). Lipids Health Dis. 2007;6:23.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Peterfy M, Ben-Zeev O, Mao HZ, Weissglas-Volkov D, Aouizerat BE, Pullinger CR, et al. Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia. Nat Genet. 2007;39:1483–7.View ArticlePubMedGoogle Scholar
  17. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000;86:943–9.View ArticlePubMedGoogle Scholar
  18. Athyros VG, Giouleme OI, Nikolaidis NL, Vasiliadis TV, Bouloukos VI, Kontopoulos AG, et al. Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. J Clin Gastroenterol. 2002;34:472–5.View ArticlePubMedGoogle Scholar
  19. Hopkins PN, Wu LL, Hunt SC, Brinton EA. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol. 2005;45:1003–12.View ArticlePubMedGoogle Scholar

Copyright

Advertisement